Firtecan pegol

N/A

Report date: 2024/01/29 17:45:37
NME

Base Information

Drug NameFirtecan pegol
Drug Alias Namefirtecanum pegolum培戈非替康培戈-菲尔替康BEL-0222PEG-SN38 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitorsHypoxia-inducible factor 1 alpha inhibitors
TargetsHypoxia-inducible factor 1 alphaDNA topoisomerase I
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEnzon Pharmaceuticals Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesEnzon Pharmaceuticals IncZhejiang Hisun Pharmaceutical Co Ltd
Inactive CompaniesNational Cancer Institute
Active IndicationsColorectal NeoplasmsBreast Neoplasms
Inactive IndicationsMetastatic breast cancerSolid tumoursLymphoma +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG